Request a Proposal
Welcome to Rapport, containing tips, truths, news and views, blogs, tweets, articles and films covering a range of topics currently affecting Research Partnership and the pharma market research world
  • Posted by Rachel Howard & Brett Gardiner
  • November 8, 2019
  • Events

ISPOR Europe Conference 2019

ISPOR Europe Conference 2019

This week, Directors Brett Gardiner and Rachel Howard attended the ISPOR Europe conference in Copenhagen, Denmark

On November 4th to 6th, Directors Brett Gardiner and Rachel Howard joined 5,500 other healthcare leaders in attending the ISPOR Europe 2019 conference in Copenhagen, Denmark. The conference opened with an announcement that four Nordic countries have pledged to spend 5% of their GDP on preventive healthcare by 2030, a significant investment in the health of these Nations. This was a timely announcement given the three-day program of events centered around the theme of ‘Digital Transformation of Healthcare’.

read more »

China: How to strategise and win in the world's fastest changing healthcare market

China: How to strategise and win in the world's fastest changing healthcare market

In this paper, our experts Marc Yates, Pei Li Teh and Brett Gardiner discuss the China healthcare reforms which affect pharma and propose how to build the market understanding required to launch a brand effectively in this exciting region.

With a population of 1.4 billion people China has always been an attractive prize to the pharmaceutical industry. However, China has historically been a tough market to crack and few multinational companies have seen a good return on their investment. But in 2019, the 70th anniversary of the communist party’s victory, the outlook has changed completely and now pharma is rushing to leverage the many opportunities that China offers.

read more »

  • Posted by Rachel Howard
  • October 23, 2019
  • Articles

Market access in Brazil: All eyes on Spinraza

Market access in Brazil: All eyes on Spinraza

Director Rachel Howard asks, “What does Brazil’s unprecedented risk-sharing agreement in Spinal Muscular Atrophy (SMA) mean for the future of market access in Brazil?

In April 2019, Brazilian Health Minister Luiz Henrique Mandetta announced a pilot agreement for access to Biogen’s Spinal Muscular Atrophy (SMA) treatment Spinraza (nusinersen) through the Sistema Único de Saúde (SUS). This is the first agreement in Brazil to include a risk-sharing model, in which the government only pays for the drug if there is improvement in the patient's health. In a country where it typically takes years for innovative pharmaceutical products to be reimbursed in the public sector, manufacturers wishing to obtain market access for their products in Brazil will be watching this example closely to see how it plays out.

read more »

How we helped our client understand current and future combination pricing strategies in the Multiple Myeloma market

How we helped our client understand current and future combination pricing strategies in the Multiple Myeloma market

Our client had their product  for multiple myeloma (MM) approved in several lines of therapy combined with different backbones. Their product was also being studied in some other indications with additional backbones and was anticipated to receive approval in the coming years. With several other competitive therapies available on the market, including many branded combination products, our client anticipated that payers might start considering strategies to manage combination therapies in the future. Therefore, they wanted to understand what the current and future combination pricing strategies were for oncology products, with a focus on MM and their product.

read more »

How we helped assess the asthma market landscape in emerging markets

How we helped assess the asthma market landscape in emerging markets

Our client was jointly developing a fully-human monoclonal antibody (mAB) with a number of potential immunological indications. In order to prepare for launch, primary and secondary market research was required to understand more fully the asthma landscape.

read more »